As previously disclosed, on November 2, 2026, Karyopharm Therapeutics Inc. (the “Company”) and its subsidiary, KPT Texas LLC (together with the Company, the “Debtors”) filed voluntary petitions (the “Bankruptcy Petitions”) under Chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of Texas, Houston Division (such court, the “Court” and such cases, the “Cases”). On November 4, 2026, the Company received written notice (the “Delisting Notice”) from the staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, as a result of the Bankruptcy Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq determined that the Company’s securities will be delisted from Nasdaq.
|
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule XPO1 inhibitors for the treatment of cancer. Its lead asset, XPOVIO (selinexor), is an oral XPO1 inhibitor approved in the U.S. for multiple myeloma and diffuse large B-cell lymphoma, and marketed as NEXPOVIO in Europe and the UK. The company is advancing clinical programs for selinexor in myelofibrosis and endometrial cancer, while developing next-generation XPO1 inhibitor eltanexor for myeloproliferative neoplasms and TP53 wild-type tumors. Karyopharm commercializes XPOVIO in the U.S. through its own sales force and the KaryForward patient support program, while partnering with the Menarini Group for commercialization in territories outside the U.S. Summarised from the company's own disclosures, fiscal year ended Feb 2026 |
Industry Drug Manufacturers - General | Homepage karyopharm.com |
| Sector Healthcare | IR page investors.karyopharm.com | |
|
Tags
oncology, multiple myeloma, myelofibrosis, endometrial cancer, lymphoma, xpo1 inhibitors, nuclear export inhibition, small molecule drugs, clinical-stage pipeline, XPOVIO, selinexor, NEXPOVIO, eltanexor, KaryForward, Menarini Group
|
Press page investors.karyopharm.com/press-releases |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 7.802M |
| Market cap (USD) | $ 7.802M |
| P/E | -0.02 |
| PEG | — |
| P/BV | -0.02 |
| P/S | 0.05 |
| P/OCF | -0.12 |
| P/FCF | -0.10 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 66.9% |
| ROI | — |
| ROIC | — |
| Profit margin | -134.2% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | Yes |
| Buying back stock | — |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 70 |
| Quality score | -46.2% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 146.067M | 145.237M | 146.033M | 157.074M | 209.819M | 108.085M | 40.893M | 30.336M | — | 154K | 250K | 229K | 387K | 634K |
| Net profit | -196.039M | -76.422M | -143.099M | -165.291M | -124.088M | -196.273M | -199.59M | -178.407M | -128.984M | -109.577M | -118.181M | -75.777M | -33.947M | -15.888M |
| Free cash flow | -75.369M | -127.628M | -92.723M | -149.672M | -107.328M | -160.379M | -191.028M | -161.48M | -73.779M | -84.461M | -95.445M | -54.281M | -30.347M | -15.63M |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | — | — | — | 7.86M | 12.9M | 22.5M | 47.1M | 27M | 30.8M | 26.2M |
| ↳ YoY growth | +64.1% | +74.4% | +109.3% | -42.7% | +14.1% | -14.9% | ||||
| ↳ 5y CAGR | +31.4% | +15.2% | ||||||||
| Lease liabilities (USD) | — | — | 14.8M | 14.8M | 13.2M | 11.3M | 8.97M | 6.1M | 7.15M | 6.71M |
| Cash and deposits (USD) | 49.7M | 69M | 118M | 129M | 85.9M | 190M | 135M | 52.2M | 62.5M | 60.5M |
| Right-of-use assets (USD) | — | — | 11.7M | 10.6M | 9.36M | 7.92M | 6.24M | 4.28M | 5.88M | 4.55M |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | -84.4M | -73.7M | -159M | -191M | -160M | -107M | -150M | -92.7M | -127M | -75.4M |
| Purchases of property, plant and equipment (USD) | -70,000 | -62,000 | -2.36M | -206,000 | -145,000 | -212,000 | -118,000 | 0.00 | -142,000 | 0.00 |
| Change in receivables (cash effect) (USD) | — | — | — | -7.86M | -5.02M | -9.62M | -5.08M | 20.1M | -3.8M | 4.59M |
| Change in inventories (cash effect) (USD) | — | — | — | -346,000 | -2.63M | -1.46M | -118,000 | 1.18M | -1.7M | 701,000 |
| Change in payables (cash effect) (USD) | 945,000 | 909,000 | -1.38M | -3.3M | 3.47M | -2.85M | 1.17M | 350,000 | 1.98M | -1.1M |
| Interest paid (cash effect) (USD) | — | — | — | — | -5.18M | -5.18M | -5.18M | -5.18M | -17.1M | -10.7M |
| Share-based compensation (USD) | 22.3M | 20.4M | 17.3M | 15.3M | 24.4M | 29.8M | 35.4M | 21.7M | 18.4M | 14.1M |
| Operating cash flow before change in receivables (USD) | — | — | — | -183M | -155M | -97.5M | -144M | -113M | -124M | -80M |
| Free cash flow (OCF - PPE - intangibles) (USD) | -84.5M | -73.8M | -161M | -191M | -160M | -107M | -150M | -92.7M | -128M | -75.4M |
| Income detail | ||||||||||
| Research and development expense (USD) | 86.9M | 107M | 161M | 122M | 151M | 161M | 149M | 139M | 143M | 126M |
| ↳ 5y CAGR | +58.7% | +50.1% | +41.5% | +15.3% | +9.1% | +13.1% | +6.7% | -3.0% | +3.2% | -3.6% |
| Total comprehensive income (USD) | -110M | -129M | -178M | -199M | -196M | -124M | -166M | -143M | -76.6M | -196M |
| Comprehensive income to owners (USD) | -110M | -129M | -178M | -199M | -196M | -124M | -166M | -143M | -76.6M | -196M |
| Reported | Mar 16, 2017 | Mar 15, 2018 | May 9, 2019 | Feb 26, 2020 | Feb 17, 2023 | Feb 17, 2023 | Feb 17, 2023 | Feb 29, 2024 | Feb 19, 2025 | Feb 13, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
– Week 48 Data from the Phase 3 SENTRY Trial Selected for Oral Presentation –
– Data from the Phase 2 SENTRY-2 Trial Selected for Oral Presentation –
NEWTON, Mass., Nov. 4, 2026 /PRNewswire / -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm" or the "Company"), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that abstracts from two of its clinical trials evaluating selinexor in patients with myelofibrosis were selected for oral presentations at ASH 2026. In addition, an abstract from a clinical trial evaluating selinexor in combination with other backbone therapies in multiple myeloma was selected for a poster presentation.
"New data from SENTRY continues to highlight the promising clinical activity achieved with the combination of selinexor plus ruxolitinib in patients with myelofibrosis, with ongoing benefit observed through week 48," said Reshma Rangwala, M.D., Ph.D., Chief Medical Officer and Head of Research of Karyopharm. "I am also encouraged by early data from the Phase 2 SENTRY-2 trial where selinexor is being evaluated as a monotherapy, with an optional add-on of a JAK inhibitor. Data from the 60 mg cohort of SENTRY-2 support monotherapy selinexor activity in JAKi-naïve myelofibrosis."
Phase 3 SENTRY 48 Week Data Oral Presentation Details - Myelofibrosis
- Title: Updated results from the Phase 3 SENTRY trial investigating selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis
- Publication Number: 526
- Session Title: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Combining Forces Against Myelofibrosis
- Presentation Time: December 13, 2026 from 10:15 a.m. CT to 10:30 a.m. CT
Phase 2 SENTRY-2 Monotherapy Data Oral Presentation Details - Myelofibrosis
- Title: Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naïve myelofibrosis
- Publication Number: 244
- Session Title: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Emerging Therapies and Approaches in MPN
- Presentation Time: December 12, 2026 from 2:45 p.m. CT to 3:00 p.m. CT
Phase 1b/2 STOMP Arm 12 Poster Presentation Details – Multiple Myeloma
- Title: Selinexor, mezigdomide, and dexamethasone (SMd) in patients with relapsed/refractory multiple myeloma (RRMM) who relapsed or are ineligible for T-cell–redirecting therapy: updated results from STOMP Arm 12
- Publication Number: 2242
- Session Title: 654. Multiple Myeloma: Pharmacologic Therapies: Poster I
- Presentation Time: December 12, 2026 from 5:30 p.m. CT to 7:30 p.m. CT
About the Phase 3 SENTRY Trial
SENTRY (XPORT-MF-034; NCT04562389 ) is a Phase 3 clinical trial evaluating a once-weekly dose of 60 mg of selinexor in combination with ruxolitinib compared to placebo plus ruxolitinib in JAKi-naïve myelofibrosis patients with platelet counts >100 x 109/L (N=353). Patients were randomized 2-to-1 to the selinexor arm. The co-primary endpoints for this trial are spleen volume reduction ≥ 35% (SVR35) at week 24 and the average change in absolute total symptom score (Abs-TSS) over 24 weeks relative to baseline. The results from the Phase 3 SENTRY trial were presented at the 2026 American Society of Clinical Oncology Annual Meeting and were simultaneously published in the peer-reviewed Journal of Clinical Oncology. In addition, the results were presented at the 2026 European Hematology Association Congress, where the presentation was recognized as one of the six best abstracts at the meeting.
About the Phase 2 SENTRY-2 Trial
SENTRY-2 (XPORT-MF-044; NCT05980806 ) is a multicenter, open-label, Phase 2 study evaluating the efficacy of selinexor monotherapy (cohort 1: 60 mg once-weekly; n=29 per arm) in patients with JAKi-naïve myelofibrosis and thrombocytopenia (platelet count ≥50x109/L). Optional ruxolitinib, pacritinib, or momelotinib treatment (based on platelet count) could be added for patients whose SVR from baseline is <10% at Week 12 or <35% at Week 24. The primary endpoint is spleen volume reduction ≥35% (SVR35) at Week 24. Key secondary endpoints are safety and absolute total symptom score (Abs-TSS) at Week 24. Exploratory endpoints include changes in variant allele frequency (VAF) and bone marrow fibrosis.
About Myelofibrosis
Myelofibrosis is a rare blood cancer that affects approximately 20,000 patients in the United States and 19,000 patients in the European Union1. The disease causes bone marrow fibrosis (scarring in the bone marrow), which makes it difficult for the bone marrow to make healthy blood cells, splenomegaly (enlarged spleen), progressive anemia which often leads to symptoms like fatigue and weakness, and other disease associated symptoms including abdominal discomfort, pain under the left ribs, early satiety, night sweats and bone pain. The only approved class of therapies to treat myelofibrosis are JAK inhibitors, including ruxolitinib.
1. Clarivate/DRG (2023)
About STOMP Arm 12
Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP; NCT02343042 ) Arm 12 is evaluating the all-oral combination of selinexor, mezigdomide, and dexamethasone (SMd) in adults with triple-class exposed relapsed/refractory multiple myeloma with ≥2 prior lines of therapy and who had progressed after or were deemed ineligible for T-cell-redirecting therapy (TCRT). Phase 1 had 3 cohorts with the selinexor dose escalated from 40 mg once weekly to 60 mg on days 1, 8, and 15 of a 28-day cycle; mezigdomide is administered at 0.6 or 1.0 mg daily on days 1–21, and dexamethasone 40 mg is administered weekly. Responses are assessed by investigator using International Myeloma Working Group criteria, and safety is assessed per Common Terminology Criteria for Adverse Events (CTCAE) V5.0. Phase 1 objectives are to determine maximum tolerated dose and recommended Phase 2 dose (RP2D) of SMd; Phase 2 primary objectives are to determine objective response rate (ORR) and further characterize safety as per CTCAE V5.0 at the RP2D.
About XPOVIO® (selinexor)
XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved and marketed by Karyopharm in the U.S. in multiple oncology indications, including: (i) in combination with VELCADE® (bortezomib) and dexamethasone (XVd) in adult patients with multiple myeloma after at least one prior therapy; and (ii) in combination with dexamethasone in adult patients with heavily pre-treated multiple myeloma. XPOVIO® (also known as NEXPOVIO® in certain countries) has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including but not limited to the European Union, the United Kingdom, Mainland China, Taiwan, Hong Kong, Australia, South Korea, Singapore, Israel, and Canada. XPOVIO®/NEXPOVIO® is marketed in these respective ex-U.S. territories by Karyopharm's partners: Antengene, Menarini, Neopharm, and FORUS. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high-unmet need cancer indications.
– The Company Remains Focused on Supporting Patients and Advancing its Programs in Multiple Myeloma and Myelofibrosis –
– Ayrmid will Serve as Lead Bidder in Court-Supervised Sale Process to Maximize Business Value for all Stakeholders –
– The Company Receives a Commitment of $55 Million in Additional Financing and Ongoing Operations Are Expected to be Uninterrupted During Sale Process –
NEWTON, Mass., November 2, 2026 – Karyopharm Therapeutics Inc. (Nasdaq: KPTI) (“Karyopharm” or the “Company”), a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced today it has entered into a Restructuring Support Agreement with its existing lenders and noteholders and other key stakeholders, which provides for a merger between Ayrmid Ltd. (“Ayrmid”) and a reorganized Karyopharm (the “Transaction”). During this process, Karyopharm remains focused on its commitment to advancing its multiple myeloma and myelofibrosis programs and improving the lives of the patients Karyopharm serves and will continue to operate in the ordinary course of business.
To implement the Transaction, Karyopharm has filed voluntary petitions under Chapter 11 of the U.S.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Karyopharm Therapeutics Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.




